You have read all your free articles, to continue reading subscribe to read the rest of this content.
New results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of Farxiga, compared to placebo, in patients with heart failure (HF). The reduction in risk of cardiovascular (CV) death was consistent across pre-specifieAlready a subscriber Login You have read all…
Biovica has been selected by the European Commission to receive support for a project as part of the Horizon 2020 phase 2 program. Biovica’s project “Clinical validation of the DiviTum assay in two high profile clinical studies in Europe” is receiving € 682,000 and being undertaken with a EuAlready a…
Elypta has announced the launch of a clinical study intended to validate the diagnostic performance of GAGomes – the complete profile of human glycosaminoglycans – as metabolic biomarkers for Multi-Cancer Early Detection (MCED). The study, LEVANTIS-0087A (LEV87A), aims to detect any-type cancAlready a subscriber Login You have read all your…
All patients in the company's phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial and no dose limiting toxicities (DLTs) were reported at the highest dose level investigated, 10 mg/kg. According to the study protocol, the patients continue CANAlready a subscriber…
